Okta is trading at $196.62 — up 3% on the week and 45% over the past month — and the tension this week is no longer about whether the rally is real, but whether options traders are finally starting to believe it.
The clearest signal sits in options positioning. The put/call ratio has collapsed to 1.04, more than three standard deviations below its 20-day average of 1.26 — the most bullish relative reading in at least a year, and a sharp reversal from the defensive posture that dominated through August and early September. For weeks, the PCR held stubbornly above 1.27, hitting its 52-week high of 1.34 in late August. The move below 1.10 this week is abrupt. Options traders who were paying up for puts — whether hedging into the August earnings or fading the post-earnings surge — have rotated away from downside protection at a pace the 20-day window barely captures. The borrow market reinforces the picture: availability is exceptionally loose at 3,844%, meaning there are roughly 38 shares available to lend for every one currently borrowed. Cost to borrow remains low at 0.45%. There is no squeeze pressure, no tight lending dynamic, no short-side urgency — just a very comfortable borrow environment for a stock that shorts have been treating with increasing caution.
Short interest itself has pulled back modestly. At 4.55% of free float — down 3% on the week — it remains elevated relative to where it was before the August earnings print, when shorts held around 6.4 million shares. The rebuild that followed the 32% single-day surge after earnings (documented in the September 17 note) has stalled. Shorts added aggressively between September 9 and September 16, pushing SI from roughly 6.5 million to over 8.1 million shares. They have been quietly trimming since. The short score has tracked that retreat, falling from 38.0 on September 10 to 36.5 now — not a dramatic move, but a consistent direction.
The Street has kept busy. Scotiabank raised its target to $190 from $165 this week, maintaining Sector Outperform. Baird lifted to $200 from $185, also holding Outperform. Needham went further, pushing its Buy target to $230 from $200 — the highest on the board among recent movers. These follow BofA's $200 raise last week (still Neutral, which remains the awkward outlier in an otherwise constructive tape). The consensus mean target now stands at $186.92, which is already below the current price of $196.62. That inversion is meaningful: after a 45% one-month run, the stock has outrun where the average analyst thought it would go. Bulls point to accelerating cRPO, expanding enterprise wins, and early positioning in AI agent security. Bears — anchored by Bernstein's Market Perform downgrade last week — argue the valuation is stretched, with a trailing P/E near 46 and EV/EBITDA at 34x. The P/B multiple has expanded roughly 50% in 30 days, a pace that is hard to sustain without a step-change in earnings delivery.
On the ownership side, FMR raised its stake to 11.6% in an August 13D/G filing, up from 9.8% previously — a meaningful addition from Okta's largest disclosed holder. No 13D activists are on the register. Todd McKinnon, the CEO, trimmed 58,598 shares in the most recent period per the institutional holder data, while insider sales from Eric Kelleher in mid-September were all executed under pre-arranged 10b5-1 plans, which carries limited signal on conviction. Net insider value over 90 days is a modest -$1.17 million — not alarming given the scale of the move.
The next earnings date is December 2. Between now and then, the story is whether the Street closes the gap between a $186 consensus target and a stock already trading at $197 — or whether analysts catch up with more upgrades while the options market's newfound bullishness holds.
See the live data behind this article on ORTEX.
Open OKTA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
